Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288581 | 0.90 | KMT2A (0.46) | L3MBTL1PLK1HPGDLMNAALDH1A1 | |
| SCHEMBL4287147 | 0.83 | LMNA (0.44) | HPGDLMNAALDH1A1KMT2AMAPK1 | |
| SCHEMBL4287440 | 0.76 | KMT2A (0.47) | L3MBTL1PLK1HPGDLMNAHTT | |
| SCHEMBL4288403 | 0.75 | NPSR1 (0.46) | L3MBTL1PLK1HPGDLMNAALDH1A1 | |
| SCHEMBL6341040 | 0.73 | L3MBTL1 (0.68) | L3MBTL1PLK1LMNAKMT2ACYP19A1 | |
| SCHEMBL4288059 | 0.73 | L3MBTL1 (0.49) | L3MBTL1PLK1HPGDLMNAALDH1A1 | |
| SCHEMBL11578668 | 0.69 | KMT2A (0.67) | L3MBTL1PLK1HPGDLMNAALDH1A1 | |
| SCHEMBL4279762 | 0.69 | LMNA (0.45) | HPGDLMNAALDH1A1KMT2AMAPK1 | |
| SCHEMBL4284546 | 0.69 | LMNA (0.45) | HPGDLMNAALDH1A1KMT2AMAPK1 | |
| SCHEMBL13845292 | 0.68 | LTA4H (0.68) | L3MBTL1PLK1HPGDLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2048150-A1 | BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | L3MBTL1 2087/4885PLK1 4871/4885HPGD 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.